arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Nuvectis Pharma, Inc.

NVCT

$18.91 ▲ +0.09 (+0.48%) at close

22 Visible periods

17 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Nuvectis Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $442.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -34.8% ↘

FCF / Share $-0.28

Trailing P/E —

Price / Book 35.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-6.05M

↓ -13.5% —

FCF / Share Free cash flow per share

$-0.28

↓ -32.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↓

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2020

FY 2021

$0.00

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
EPS Growth YoY (%)	3.7% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	13.9% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-83.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-15.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-8.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	12.2% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	35.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	31.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	7.4% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	14.6% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	11.9% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-35.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	0.0% Caution ↓ Caution Declining Year-over-year change in earnings per share Optimal: > 10%	59.6% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	80.4% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	3100.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-13.5% Weak ↑ Weak Improving Year-over-year change in net income	-17.1% Weak ↑ Weak Improving Year-over-year change in net income	-27.8% Weak ↓ Weak Declining Year-over-year change in net income	-27.8% Weak ↓ Weak Declining Year-over-year change in net income	-27.8% Weak ↓ Weak Declining Year-over-year change in net income	5.6% Fair ↑ Fair Improving Year-over-year change in net income	-3.0% Weak ↓ Weak Declining Year-over-year change in net income	-3.0% Weak ↑ Weak Improving Year-over-year change in net income	-3.0% Weak ↑ Weak Improving Year-over-year change in net income	1.1% Caution ↑ Caution Improving Year-over-year change in net income	-37.6% Weak ↑ Weak Improving Year-over-year change in net income	-37.6% Weak ↑ Weak Improving Year-over-year change in net income	-37.6% Weak ↑ Weak Improving Year-over-year change in net income	-196.2% Weak ↑ Weak Improving Year-over-year change in net income	-12695.7% Weak → Weak Stable Year-over-year change in net income	-12695.7% Weak Weak Year-over-year change in net income	-12695.7% Weak Weak Year-over-year change in net income	—	—	—	—	—
FCF Growth YoY (%)	-32.8% Weak Weak Year-over-year change in free cash flow	—	—	—	20.5% Good Good Year-over-year change in free cash flow	—	—	—	18.9% Good Good Year-over-year change in free cash flow	—	—	—	3.4% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.63x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.39x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.04x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.18x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.53x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	1.05x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	192.43x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-34.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-21.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-52.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-31.3% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-29.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-44.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.2% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-26.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-37.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	16.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	41.3% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	106.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	181.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-24.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-21.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-18.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-35.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-23.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-16.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-34.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-42.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-384%)	-39.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-365%)	-22.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-248%)	-31.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-311%)	-25.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-270%)	-64.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-529%)	-37.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-353%)	-33.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-322%)	-29.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-298%)	-54.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-462%)	-24.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-262%)	-19.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-233%)	-33.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-320%)	-47.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-414%)	-14.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-196%)	-25.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-271%)	-20.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-235%)	20.5% Excellent ↓ Excellent Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+37%)	0.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-98%)	0.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-97%)	230.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1433%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Debt (USD)	$-25.13M	$-31.63M	$-35.44M	$-26.79M	$-29.86M	$-18.53M	$-17.17M	$-18.12M	$-19.46M	$-19.13M	$-22.06M	$-24.60M	$-15.47M	$-19.99M	$-23.64M	$-13.57M	$-16.69M	$-5.74M	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.26	$-0.31	$-0.44	$-0.30	$-0.27	$-0.36	$-0.24	$-0.26	$-0.25	$-0.41	$-0.37	$-0.38	$-0.27	$-0.48	$-0.42	$-0.28	$0.32	$-0.48	$-1.04	$-1.43	$0.01	—
Free Cash Flow per Share (USD)	$-0.28	—	$-0.20	$-0.16	$-0.21	—	—	—	$-0.26	—	—	—	$-0.32	—	—	—	$-0.34	—	$-0.98	—	—	—
Book Value per Share (USD)	$0.54	$0.72	$0.94	$0.71	$0.89	$0.50	$0.58	$0.67	$0.76	$0.70	$0.96	$1.18	$0.83	$0.94	$1.39	$0.90	$1.14	$-2.44	$-1.98	$-1.06	$-0.00	—
Tangible Book Value per Share (USD)	$0.54	$0.72	$0.94	$0.71	$0.89	$0.50	$0.58	$0.67	$0.76	$0.70	$0.96	$1.18	$0.83	$0.94	$1.39	$0.90	$1.14	$-2.44	$-1.98	$-1.06	$-0.00	—
Basic Weighted Avg Shares (shares)	23.41M	—	22.72M	21.37M	19.94M	—	17.23M	16.90M	16.56M	—	16.10M	15.18M	14.72M	—	14.05M	12.72M	9.16M	—	4.51M	4.16M	3.90M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$14.22M	$18.41M	$24.01M	$16.87M	$20.95M	$9.71M	$10.99M	$12.53M	$14.02M	$12.20M	$16.69M	$20.33M	$12.27M	$14.22M	$20.37M	$11.50M	$14.56M	$3.41M	—	—	—	—
Total Equity (USD)	$14.22M	$18.41M	$24.01M	$16.87M	$20.95M	$9.71M	$10.99M	$12.53M	$14.02M	$12.20M	$16.69M	$20.33M	$12.27M	$14.22M	$20.37M	$11.50M	$14.56M	$-11.01M	$-8.93M	$-4.40M	$-10.00K	$-10.00K

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q3 FY2022 Sep 30, 2022 10-Q ↗	Q2 FY2022 Jun 30, 2022 10-Q ↗	Q1 FY2022 Mar 31, 2022 10-Q ↗	Q4 FY2021 Dec 31, 2021 10-K ↗	Q3 FY2021 Sep 30, 2021 10-Q ↗	Q2 FY2021 Jun 30, 2021 10-Q ↗	Q1 FY2021 Mar 31, 2021 10-Q ↗	Q4 FY2020 Dec 31, 2020 10-K ↗
Net Income, GAAP (USD)	$-6.05M	$-7.31M	$-5.33M	$-5.33M	$-5.33M	$-6.25M	$-4.17M	$-4.17M	$-4.17M	$-6.62M	$-4.05M	$-4.05M	$-4.05M	$-6.70M	$-2.94M	$-2.94M	$-2.94M	$-2.26M	$-23.00K	$-23.00K	$-23.00K	—
Operating Cash Flow (USD)	$-6.51M	$-3.97M	$-4.49M	$-3.37M	$-4.17M	$-2.46M	—	—	$-4.36M	$-3.85M	—	—	$-4.78M	$-3.52M	—	—	$-3.08M	$-1.07M	$-4.43M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters

Nuvectis Pharma, Inc.

Analytical Summary

22-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NVCT with peers